Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

In 2024, Novo Nordisk A/S (NYSE:NVO) made significant progress in obesity treatments like CagriSema, semaglutide 7.2 mg, and amycretin ... laptops, tablets, and mobile devices.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

NCT05564117), a 64-week study that included a 12-week dose escalation and a 7-week off-treatment follow-up period. Study participants were randomly assigned 2:1 to receive oral semaglutide 25 mg ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%. 1 Left untreated, MASH ...

25 mg oral formulation of Wegovy® (semaglutide) for chronic weight management in adults living with obesity or overweight with one or more comorbid conditions and to reduce the risk of major ...

and a 7-week off-treatment follow-up period.1,3 In total, 307 participants were randomized 2:1 ratio to once-daily oral semaglutide 25 mg or placebo, as an adjunct to lifestyle intervention for 64 ...

"We are entering a new era of obesity care where patients want individualized treatment plans that address their needs and provide choices, including oral formulations," said Anna Windle, PhD ...